Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bridget Moreno

Nurse Practitioner San Antonio, TX Nurse Practitioner

NPI 1306882139 CMS profile 10587720

343 W Houston St, Suite 725, San Antonio, TX 78205

Open in the dashboard

General payments

$4,382

218 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bridget Moreno of San Antonio, TX is reported in the CMS Open Payments database as having received $4,382 across 218 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $742 31
2024 General $1,201 60
2023 General $934 51
2022 General $838 44
2021 General $666 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bridget Moreno
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Bridget Moreno were reported at $742. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Bridget Moreno Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $666 $135 $40–$426 $132
2022 $838 $152 $48–$470 $149
2023 $934 $166 $54–$529 $160
2024 $1,201 $173 $55–$556 $164
2025 $742 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $996 51 payments
  2. Teva Pharmaceuticals USA, Inc. $794 37 payments
  3. Janssen Pharmaceuticals, Inc $557 26 payments
  4. Otsuka America Pharmaceutical, Inc. $413 23 payments
  5. Neurocrine Biosciences, Inc. $312 13 payments
  6. Lundbeck LLC $287 16 payments
  7. Vanda Pharmaceuticals Inc. $173 9 payments
  8. Sunovion Pharmaceuticals Inc. $171 10 payments
  9. E.R. Squibb & Sons, L.L.C. $129 5 payments
  10. Supernus Pharmaceuticals, Inc. $101 6 payments
  11. Other $448 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,382 218 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA Psychiatry $748 41 payments
  2. AUSTEDO $394 17 payments
  3. Austedo XR $375 19 payments
  4. INVEGA SUSTENNA $357 16 payments
  5. REXULTI $334 19 payments
  6. INGREZZA $299 12 payments
  7. CAPLYTA Psychiatry $248 10 payments
  8. INVEGA TRINZA $217 8 payments
  9. SPRAVATO $200 10 payments
  10. FANAPT $173 9 payments
  11. Other $1,672 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

218 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record